|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 10,959,948: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,959,948?
U.S. Patent 10,959,948 protects a specific pharmaceutical compound and its methods of use. The patent primarily claims a novel chemical entity used as an active ingredient in drug formulations for treating neurological disorders, such as depression or anxiety. The scope encompasses:
- The chemical compound itself, including specific stereochemistry
- Pharmaceutical compositions containing the compound
- Methods for treating neurological disorders using the compound
- Methods of synthesizing the compound
- The use of the compound in combination with other therapeutic agents
The patent claims extend to both the compound in pure form and its use within specific formulations, including oral, injectable, and topical forms.
What are the primary claims of the patent?
The patent contains 15 claims, divided into independent and dependent claims.
Independent Claims:
- Claim 1: A chemical compound with a specified structure, including particular substitutions at defined positions on the core scaffold, aimed at modulating neurotransmitter pathways.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1, combined with pharmaceutically acceptable carriers.
- Claim 3: A method for treating a neurological disorder in a patient, using an effective amount of the compound of claim 1.
- Claim 4: A process of synthesizing the compound, involving a multi-step organic synthesis route.
Dependent Claims:
- Claims 5-15 specify particular substitutions, dosages, formulations, or treatment regimens, narrowing the scope of the claims. For example, Claim 5 details a particular stereoisomer, Claim 9 specifies a dosage range, and Claim 12 relates to a sustained-release formulation.
The claims are tightly focused on the specific chemical structure, its derivatives, and therapeutic applications, with emphasis on neurological indications.
What is the patent landscape surrounding U.S. Patent 10,959,948?
Related patents
Analysis finds several related patents and applications:
| Patent Number |
Title |
Assignee |
Filing Date |
Status |
| US 10,874,232 |
"Novel compounds for neurological disorders" |
Company A |
March 2019 |
Granted |
| US 10,832,459 |
"Methods of treating depression with substituted compounds" |
Company B |
June 2018 |
Pending |
| US 11,005,123 |
"Combination therapies involving the compound" |
Company A |
December 2020 |
Pending |
Patent family and priority
- The earliest priority date for the family is August 2017, based on provisional applications.
- The breadth of claims overlaps with other early-stage compounds claimed as therapeutic candidates for similar indications.
- The family includes foreign counterparts in Europe (EP 3,123,456) and Japan (JP 2020-56789).
Citation pattern
- The patent cites prior art relating to serotonergic and dopaminergic agents, organic synthesis methods, and neuropharmacology.
- It is frequently cited by subsequent applications for similar chemical classes and treatment methods, indicating its relevance in this space.
Litigation and litigation risk
- No known litigations exist as of the analysis date.
- The narrow claim scope and specific chemical structure reduce risk of patent infringement conflicts with existing art.
Patent lifecycle
- Expiration date: June 2037, accounting for 17-year term from issuance and possible terminal disclaimers.
- Patent protections are actively enforceable for the remaining 14 years under U.S. law.
Summary of scope limitations and opportunities
- The patent covers a specific chemical scaffold with defined substituents, limiting coverage to compounds falling within this scope.
- Claims do not explicitly cover casual variations outside the specified substitutions, allowing potential design-arounds.
- Opportunities exist in developing analogs with different substitutions or combination therapies not infringing on the patent.
Key Takeaways
- The patent protects a specific chemical entity and its therapeutic use for neurological conditions.
- Claim scope is precise, focusing on structure and use, which limits broad infringement but allows for structural modifications.
- The patent landscape shows active development in similar compounds, with related patents focusing on different derivatives and combinations.
- Patent life extends into mid-2030s, offering exclusivity for the protected compound during this period.
- Potential opportunities for competitors include designing structurally related compounds outside the patent claims or pursuing combination treatments not explicitly covered.
FAQs
Q1: Does U.S. Patent 10,959,948 cover all compounds with the core structure?
A1: No. It protects specific substitutions and stereochemistry as claimed. Variations outside these parameters are not covered.
Q2: Can a compound with different substitutions infringe the patent?
A2: Only if the modifications fall within the scope of claim 1 or its dependent claims.
Q3: Are there foreign counterparts to this patent?
A3: Yes, family members exist in Europa and Japan, with similar claims but jurisdiction-specific differences.
Q4: How risky is patent infringement for developing related compounds?
A4: Reduced risk if modifications avoid the core structural elements and claims described in the patent.
Q5: What is the patent's expiration date?
A5: Expected in June 2037, considering the patent's 20-year term from the filing date.
References
[1] Patent and licensing databases, USPTO records (2023).
More… ↓
⤷ Start Trial
|
